CERIBELL, INC

NASDAQ: CBLL (CeriBell, Inc.)

Last update: 6 days ago, 1:16PM

26.50

-1.30 (-4.68%)

Previous Close 27.80
Volume 259,004
Price / Sales 9.57
Price / Book 9.08
52 Weeks Range
12.36 (-53%) — 28.89 (9%)
Profit Margin -62.50%
Operating Margin (TTM) -69.33%
Diluted EPS (TTM) -1.25
Quarterly Revenue Growth (YOY) 42.30%
Total Debt/Equity (MRQ) 12.03%
Current Ratio (MRQ) 17.36
Operating Cash Flow (TTM) -36.90 M
Levered Free Cash Flow (TTM) -26.02 M
Return on Assets (TTM) -17.46%
Return on Equity (TTM) -41.39%

AIStockmoo Score

1.3
From our AI Insight report's view of expected return against risk. info NA
Relative Valuation info NA
Implied Growth info NA
Valuation History info NA
Low debt. Weak profitability. Ample short-term liquidity. Negative cash flow. info
Return on Capital info NA
From our AI technical analysis of the chart. info NA
Uptrend over the past year. Trading near its 52-week high. info
Price and its moving averages are lined up in an uptrend. Its main moving average is rising. Close to its rising moving average. A recent move above resistance has not been confirmed. info
Candle Patterns info NA
Above its medium-term trend line. info
No recent price targets, so based on how targets have been revised. info
Recent news mostly positive. info
No clear net insider buying or selling. info
Institutional Flow info NA
Short Interest info NA
Market environment cautious. info
Sector lagging the market.
The pillars agree, so the score is strengthened.
Price is high against its 52-week average. info
Short-term momentum fading. info
Price is between support and resistance. info
Final Score 1.28
Show all

Market Trend

Short Term Medium Term
Industry Medical Devices (US) Mixed Mixed
Medical Devices (Global) Mixed Mixed
Stock CeriBell, Inc. Mixed Bearish

Similar Stocks

Stock Market Cap DY P/E (TTM) P/B
CBLL - - - 9.08
UFPT - - - 4.88
NNOX - - - 0.310
QTI - - - 13.92
AXGN - - - 6.12
ESTA - - - 128.59

Select this tab to load the latest available analysis.

CeriBell Inc is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. The company has developed the Ceribell System, a novel, point-of-care electroencephalography (EEG) platform designed to address the unmet needs of patients in the acute care setting. By combining proprietary, portable, and rapidly deployable hardware with sophisticated artificial intelligence (AI)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. Its products are Point-of-Care EEG, Clarity, and EEG Portal.

Sector Healthcare
Industry Medical Devices
Investment Style Small Growth
% Held by Insiders 10.54%
% Held by Institutions 84.45%

No data within this time range.

No data within this time range.

4 Positive 0 Negative 7 Neutral
Date Type Details
07 Nov 2026 Yahoo Finance CeriBell (CBLL) Climbed, What Is Behind The Fresh Attention?
CeriBell guidance hike and delirium launch draw investor focus CeriBell (CBLL) has lifted its 2026 revenue outlook to US$115 million to US$117 million, while rolling out an FDA-cleared delirium monitoring solution that now qualifies for additional CMS reimbursement. CeriBell’s guidance hike and…
06 Nov 2026 Yahoo Finance Ceribell (CBLL) Stock Gets Fair Value Bump As Analysts Back Rapid EEG Growth
Ceribell’s updated analyst narrative now centers on a fair value estimate that increased from about US$27.00 to about US$29.57 per share. This change aligns with recent Street commentary that focuses on current execution in rapid EEG, new clinical indications, and how these trends shape…
04 Nov 2026 Yahoo Finance How Raised Revenue Guidance At CeriBell (CBLL) Has Changed Its Investment Story
CeriBell reported third quarter 2026 revenue of US$29.34 million and a net loss of US$21.35 million, and raised full year revenue guidance to a range of US$115 million to US$117 million following the commercial launch of its FDA cleared delirium monitoring solution. The new delirium monitoring…
04 Nov 2026 Yahoo Finance CeriBell Inc (CBLL) (Q3 2026) Earnings Call Highlights: Record Hospital Additions and 30% ...
CeriBell Inc (CBLL) posted 30% revenue growth to $29.3 million with a record 35 new hospitals and 90% gross margin, though net loss widened to $21.4 million amid heavy growth investment.
04 Nov 2026 Yahoo Finance CeriBell, Inc. Q3 2026 Earnings Call Summary
Moby summary of CeriBell, Inc.'s Q3 2026 earnings call…
04 Nov 2026 Yahoo Finance CeriBell (CBLL) Q3 2026 Earnings Call Transcript
Management details why market penetration under 4% signals runway.
03 Nov 2026 Yahoo Finance CeriBell, Inc. (CBLL) Reports Q3 Loss, Tops Revenue Estimates
CeriBell, Inc. (CBLL) delivered earnings and revenue surprises of +4.00% and +0.70%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
03 Nov 2026 Yahoo Finance Compared to Estimates, CeriBell, Inc. (CBLL) Q3 Earnings: A Look at Key Metrics
The headline numbers for CeriBell, Inc. (CBLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
03 Nov 2026 Yahoo Finance CeriBell Q3 Earnings Call Highlights
CeriBell (NASDAQ:CBLL) reported third-quarter revenue growth of approximately 30% as the company added a record number of hospital accounts and increased usage of its seizure-monitoring platform among existing customers. Management also outlined plans to commercially launch its Delirium Monitoring S…
03 Nov 2026 Yahoo Finance Ceribell Reports Third Quarter 2026 Financial Results
SUNNYVALE, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the third quarter ended September…
02 Nov 2026 Yahoo Finance Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
Commercial launch follows successful pilot, with customers reporting improved clinical decision-making and greater confidence in care decisionsSUNNYVALE, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell” or the “Company”), a medical technology company focused on…
30 Oct 2026 Yahoo Finance Is CeriBell (CBLL) Fully Priced After A 133% One Year Run?
CeriBell has delivered a sharp move over the past year, which naturally puts its current share price under the microscope. The question for you is whether the recent trading level lines up with what the business is generating through its sales. Over the past 12 months, CeriBell has returned 133.2%…
28 Oct 2026 Yahoo Finance Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
SUNNYVALE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Scott Blumberg, CFO, will participate in a…
25 Oct 2026 Yahoo Finance 3 AI Stocks To Own In October 2026
AI risk is suddenly front-page news. Financiers are warning that high valuations and concentrated exposure in artificial intelligence could feed the next market downturn, yet the same technology is quietly reshaping how smaller specialists build tools in automation, data and machine learning. That…
24 Oct 2026 Yahoo Finance Pfizer And 2 Other AI Healthcare Stocks To Watch
Warning signs around heavily indebted AI infrastructure firms have grown louder after analysts raised the risk of a tech debt spiral, with some newer players struggling to finance data centers and high-end chips. That strain shifts attention toward more grounded uses of AI that address urgent…
20 Oct 2026 Yahoo Finance Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
SUNNYVALE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the third…
18 Oct 2026 Yahoo Finance CeriBell And These 2 AI Stocks To Watch
America’s planned AI build-out faces funding strains and project delays, yet the race to add computing power has not stopped. When big data centre projects hit financing walls, attention often shifts to smaller, more focused AI players that do not need multi billion dollar budgets to move the…
17 Oct 2026 Yahoo Finance 3 AI Healthcare Stocks To Own In October 2026
Anthropic recently suggested AI could lift the US economy by nearly 50% by 2030, which shows how much value smarter software might create. Healthcare is one of the clearest places where that shift becomes real for patients and for capital. This article unpacks three AI driven healthcare stocks from…
14 Oct 2026 Yahoo Finance Is CeriBell’s (CBLL) Expanded EEG Software Deepening Its Moat in Critical Care Monitoring?
CeriBell, Inc. previously announced that the FDA cleared new software for its Ceribell System, adding bedside brain-activity trend tools like Alpha-Delta Ratio and amplitude-integrated EEG to help clinicians interpret complex EEG data more quickly across neonatal and adult critical care settings.…
13 Oct 2026 Yahoo Finance CeriBell (CBLL) After FDA Clearance Looks Pricey Despite Stronger Adoption Hopes
CeriBell (CBLL) drew investor attention after the FDA cleared new software for its Ceribell System, expanding bedside EEG tools that help clinicians read complex brain activity data more quickly in critical care. CeriBell has seen momentum build over 2026, with the share price at $26.14 and a 90…
Show more

Technical Setup Medium

Trend order
Slope
Entry
Volume
Price and its moving averages are lined up in an uptrend. Its main moving average is rising. Close to its rising moving average. A recent move above resistance has not been confirmed.
Nearest support: 24.23 – 26.40 · strong level · tested often, may give way
Nearest resistance: 25.90 – 26.68 · moderate level

AI Technical Analysis

Portfolio

AI Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2026 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria